Founder effect contributes to the unique pattern of SARS-CoV-2 variant B.1.1.519 emergence in Alaska

4

5 Tracie J. Haan¹, Lisa K. Smith², Stephanie DeRonde², Elva House², Jacob Zidek², Diana

6 Puhak², Matthew Redlinger³, Jayme Parker², Brian M. Barnes¹, Jason L. Burkhead³, Cindy

7 Knall⁴, Eric Bortz^{3,4,*}, Jack Chen^{1,2,5,*}, and Devin M. Drown^{1,5*}

8

9 ¹ Institute of Arctic Biology, University of Alaska Fairbanks, Fairbanks, Alaska, USA

- ² Alaska Division of Public Health, State of Alaska, Fairbanks, Alaska, USA
- ³ Department of Biological Sciences, University of Alaska Anchorage, Anchorage, Alaska, USA
- ⁴ WWAMI School of Medical Education, University of Alaska Anchorage, Anchorage, Alaska,
 USA

14 ⁵ Department of Biology and Wildlife, University of Alaska Fairbanks, Fairbanks, Alaska, USA

- 16 * Corresponding authors: Devin M. Drown, dmdrown@alaska.edu; Eric Bortz
- 17 ebortz@alaska.edu; Jack Chen, jchen15@alaska.edu
- 18

15

- 19 Running title: Emergence of B.1.1.519 in Alaska
- 20 Key Words: SARS-CoV-2; COVID-19; genomic epidemiology; variant

Emergence of B.1.1.519 in Alaska

21 Abstract

22 Alaska is the largest geographic state in the United States with the lowest population 23 density and a mix of urban centers and isolated rural communities. The differences in population 24 dynamics in Alaska from the contiguous United States may have contributed to a unique pattern 25 of emergence and spread of SARS-CoV-2 variants observed in early 2021. Here we examined 26 2,323 virus genomes from Alaska and 278,635 virus genomes from the contiguous United States 27 collected between the first week of December 2020 through the last week of June 2021. We 28 focused on this timeframe because of the notable emergence and spread of the SARS-CoV-2 29 lineage B.1.1.519 observed in Alaska. We found that this variant was consistently detected in 30 Alaska from the end of January through June of 2021 with a peak prevalence in April of 77.9% 31 unlike the rest of the United States with a peak prevalence of 4.6%. In Alaska, the earlier 32 emergence of B.1.1.519 coincided with a later peak of Alpha (B.1.1.7) when compared to the rest 33 of the United States. We also observed differences in the composition of lineages and variants 34 over time between the two most populated regions of Alaska. Although there was a modest 35 increase in COVID-19 cases during the peak incidence of B.1.1.519, it is difficult to disentangle 36 how social dynamics conflated changes in COVID-19 during this time. We suggest that the viral 37 characteristics, such as amino acid substitutions in the spike protein, and a founder effect likely 38 contributed to the unique spread of B.1.1.519 in Alaska.

Emergence of B.1.1.519 in Alaska

39 Introduction

40 In late 2020 and early 2021, variants of severe acute respiratory syndrome coronavirus 2 41 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), began emerging 42 worldwide. Variants were found to contain mutations that affected transmissibility, disease 43 severity, diagnostic detection, vaccine efficacy and immune evasiveness compared to the original 44 SARS-CoV-2 virus (Wuhan-1, 2019) lineage (Walensky et al., 2021). Sustained high levels of 45 transmission, variable vaccine and infection-induced immunity, along with geographic and social 46 factors all contribute to the evolution, emergence, and spread of variants in locales across the 47 world.

Alaska is the largest state in the United States by area but has the lowest population density with approximately 1.2 people per square mile on average (US Census, 2020). Population density is highly location dependent across the state with two densely populated and highly interconnected economic regions and many sparsely populated rural areas only accessible by boat or plane. The unique community dynamics in Alaska, paired with its 800 km physical distance from the contiguous United States (hereafter, Lower 48), has the potential to contribute to unique patterns of SARS-CoV-2 variant emergence and spread.

55 Here, we report on the striking difference in prevalence of SARS-CoV-2 variant B.1.1.519 56 (Rambaut et al., 2020) between Alaska and the Lower 48 in early 2021. Based on all publicly 57 available genomes outlined in outbreak.info, B.1.1.519 has been detected in at least 72 countries. 58 At its peak, B.1.1.519 comprised around 3% of sequenced cases globally (Mullen et al., 2020) 59 with the highest prevalence observed in Mexico where the lineage was first recognized and 60 comprises 7,959 of 54,886 (14.5%) sequenced genomes (Rodriguez-Maldonado 2021). 61 B.1.1.519 was detected at relatively low levels across the Lower 48 but was never characterized 62 as a variant of concern (VOC), variant of interest (VOI), or variant being monitored (VBM) by the 63 Center for Disease Control and Prevention (CDC). In contrast, the World Health Organization

Emergence of B.1.1.519 in Alaska

64 designated B.1.1.519 a variant under monitoring (VUM) on June 20, 2021, implying the potential 65 future risk until November 2021 when Delta became the dominant variant globally (World Health 66 Organization [WHO], 2021). This classification was in part due to the several key mutations 67 B.1.1.519 encodes including amino acid substitutions T478K, P681H, and T732A in the spike (S) 68 protein, that may affect affinity to the SARS-CoV-2 receptor, human angiotensin I converting 69 enzyme-2 (hACE-2). Notably, a study examining the clinical impact of B.1.1.519 infection in 70 Mexico City found patients infected with B.1.1.519 displayed a significant increase in the severity 71 of COVID-19 respiratory tract symptoms relative to patients infected with non-B.1.1.519 variants 72 (Cedro-Tanda et al., 2021).

In this study, we report the emergence, prevalence, and viral traits of SARS-CoV-2 73 74 lineages circulating in Alaska from 2.233 sequenced specimens collected between the first week 75 of December 2020 through the last week of June 2021, after which B.1.1.519 was no longer 76 detected. Using SARS-CoV-2 sequence data from the United States available on NCBI GenBank 77 by the CDC and its contracted labs, we explore how the trend in B.1.1.519 and other variants 78 observed in Alaska compared to trends across the Lower 48. These results are used to make 79 predictions about the future of SARS-CoV-2 in Alaska and highlight the importance of continued 80 genomic surveillance for aiding efforts in controlling the pandemic.

81 Materials and Methods

82 Retrieving SARS-CoV-2 Sequence Data for Alaska

The data presented here were generated as part of the *Alaska SARS-CoV-2 Sequencing Consortium* which is a partnership between the University of Alaska and the Alaska Division of Public Health (AKDPH) with the aim to increase genomic surveillance of variants. On February 14th, 2022, we downloaded 2,323 sequences from samples collected between 2020-11-29 to 2021-06-26 available on GISAID for subsequent analysis (Shu & McCauley, 2017; Elbe & Merret,

Emergence of B.1.1.519 in Alaska

2017). Genome sequencing in Alaska is from a non-targeted sample of cases, which is the best
available approximation of random samples despite potential disparate coverage across Alaska's
economic regions. We used these data to estimate the prevalence of lineages per week on dates
beginning on Sunday.

92 Analysis of SARS-CoV-2 Sequence Data for Alaska

93 Lineages were determined by running sequences through PANGO-v 1.2.124. Pangolin v 94 3.1.20, and pangoLEARN v 2/2/22, and Scorpio v 0.3.16 (O'Toole et al., 2021). We estimated the 95 prevalence of genomes grouped by the emerging lineages including B.1.617.2 and AY 96 sublineages (Delta), B.1.1.519, B.1.427/429 (Epsilon), B.1.525 (Eta), B.1.617.1 (Kappa), 97 C.37(Lambda), B.1.526 (lota), B.1.621 (Mu), B.1.351 (Beta), P.1 (Gamma), and B.1.1.7 (Alpha). 98 Genomes that did not fall into these lineages were grouped together into the category 'Not 99 Emerging Lineage.' The number of Spike protein amino acid substitutions was determined using 100 Nextclade (v 1.13.2) with 'bad' quality genomes, as determined by Nextclade's algorithm for 101 quality, removed prior to analyses (Aksamentov et al., 2021). Nextclade's quality control 102 incorporates six individual rules based on missing data, mutations, and amino acid changes as 103 described in the online documentation.

We collected metadata on the number of cases for Alaska from the AKDPH COVID-19 CSV Files Database Cases Data B dataset on 2022-2-14 (AKDPH, 2022). We collected 2020 population estimates for economic regions of Alaska from the Alaska Department of Labor and Workforce Development population estimates page (Alaska Department of Labor and Workforce Development, 2021). Information on the timeline of COVID-19 policies (in terms of restrictions, opening, and vaccines) in Alaska was collected from the Johns Hopkins Coronavirus Resource Center (John Hopkins, 2022)

Emergence of B.1.1.519 in Alaska

111 SARS-CoV-2 Sequence Data for the Lower 48

112	On February 14th, 2022, we downloaded metadata available on GenBank for 1,331,799
113	sequences including Pangolin assignment, Isolate, and GeoLocation for all samples from the
114	United State of America collected between 2020-11-29 to 2021-06-26 sequenced by the CDC.
115	We then filtered out cases from Alaska, Hawaii, and US territories to limit our comparisons to the
116	lower 48 contiguous states. We collected daily case data with seven day rolling averages from
117	the CDC COVID Data Tracker site for the entire United States (CDC, 2022).

118 Visualizations and Statistical Analyses

We generated visualizations in RStudio (v 1.4.1106) using packages ggplot2 (v 3.3.5), ggpubr (v 0.4.0), tidyverse (v 1.3.1), and lubridate (v 1.7.10). To test for significant differences in spike glycoprotein amino acid substitutions between emerging lineages or sub-lineages, we used

122 the Wilcoxon test.

123 Results and Discussion

124 Higher prevalence of B.1.1.519 in Alaska versus the Lower 48

125 We found a striking difference in the percentage of sequenced cases, a metric that can be 126 used as an estimate of prevalence, assigned to the lineage B.1.1.519 between Alaska (Figure 127 1B) and the rest of the United States (Figure 1D) in early 2021. While the earliest detection of 128 B.1.1.519 in the United States occurred 27 December 2020 in sequence data from New York, it 129 was not until five weeks later, 4 February 2021, that B.1.1.519 was detected in sequence data 130 from Alaska. By this time in the United States, other VOCs including Alpha (B.1.1.7) and Epsilon 131 (B.1.427/429) had already emerged and were being consistently detected in sequence data. In 132 contrast, Alaska had detected a single case of Alpha and no cases of Epsilon in December of 133 2020.

Emergence of B.1.1.519 in Alaska

Unlike the Lower 48 where Alpha comprised approximately 5% of sequenced cases by the end of January, in Alaska, Alpha was not consistently detected in sequenced cases until March of 2021 (Figure 1B). By the first week of March in Alaska, B.1.1.519 had already reached an estimated 60.8% of sequenced cases compared to 4.6% in the rest of the US, which was the peak prevalence for the Lower 48 (Figure 1B). During B.1.1.519's peak in the Lower 48, Alpha made up 30.5% of sequenced cases. In Alaska, B.1.1.519 reached a peak prevalence of 77.9% by the week of 4 April 2021, 5 weeks after the peak in the Lower 48.

141 In terms of COVID-19 cases reported in Alaska, there was a sharp decline the first several 142 weeks of December 2020 followed by an increase in cases through the first week of January 2021 143 and then another decline (Figure 1A). During this time, cases in the United States increased until 144 the second week of January 2021 followed by a decline through the third week of February 2021 145 (Figure 1C). In both Alaska and the rest of the United States new COVID-19 cases remained at 146 a relatively stable rate while the cases attributed to VOC, VOI, and VBMs were rising (Figure 147 1A,C). Given the complexity of factors that affect case rates, it is difficult to attribute the 148 stabilization in cases to biological mechanisms driven by variants or behavioral and social 149 dynamics such as increased vaccination rates, social restrictions, or adherence to respiratory 150 hygiene measures during this time.

151 When B.1.1.519 first emerged in Alaska, several restrictions were in place as a result of 152 COVID-19 Public Health Disaster Emergency Declaration enacted 11 December 2020 and then 153 renewed 14 January 2021 (Figure 1A). In December, Alaska also received its initial allocations of 154 the Comirnaty vaccine (Pfizer-BioNTech BNT162b2) for frontline workers. By 11 January 2021, 155 Alaskans 65 years of age and older were eligible for both Comirnaty and Spikevax (Moderna 156 mRNA-1273). Vaccine availability was expanded to the entire public by 10 March 2021 and 157 included primarily Spikevax and Comirnaty, at which time B.1.1.519 comprised 60.8% of the 158 sequenced cases. Alaska was ahead of the Lower 48 in terms of vaccine availability and percent

Emergence of B.1.1.519 in Alaska

of the population vaccinated in early 2021, which confounds the role host immunity may have hadin variant emergence and infection dynamics.

161 Difference in the emergence of B.1.1.519 within Alaska's two most populated regions

162 Given Alaska's vast geographic expanse and limited travel options, populations of people 163 tend to interact more frequently within economic regions of the state. In Alaska there are six 164 economic regions defined by the Department of Labor and Workforce Development: the 165 Anchorage-Mat Su, Interior, Gulf Coast, Southeast, Southwest, and Northern regions in order 166 from highest to lowest population. Based on available but limited data, we observed distinct trends 167 in SARS-CoV-2 across economic regions of Alaska (Figure S1). However, in our analysis, we 168 excluded all but the two most populous economic regions, the Anchorage-Mat Su and Interior, 169 because of the low proportion of sequenced cases in the other economic regions of the state. We 170 can draw more robust conclusions about estimates of prevalence because these two regions 171 sequenced greater than 5% of the newly reported cases February through June of 2021 (Figure 172 S2).

Between the Anchorage-Mat Su and Interior economic regions there were distinct dynamics in the prevalence of variants over time (Figure 2). For example, Alpha established itself earlier in the Anchorage-Mat Su than the Interior, 360 miles apart. In the Interior, Epsilon comprised a high percentage of sequenced cases from January through March 2021, and the emergence and persistence of B.1.1.519 differed between these two regions of the state.

The first case of B.1.1.519 in Alaska was detected from a sample collected 4 February 2021 in the Southwest region of the state. In both the Anchorage-Mat Su and Interior regions, B.1.1.519 was detected in specimens with collection dates one day apart from one another, 7 and 8 February 2021, respectively. By the end of February, B.1.1.519 comprised 37.8% of sequenced cases in the Anchorage-Mat Su region and 10.5% of cases in the Interior (Figure 2). By February VBMs detected in the Anchorage-Mat Su included Alpha, Epsilon, and Gamma. On the other

Emergence of B.1.1.519 in Alaska

hand, in the Interior, Epsilon was the only VBM detected and comprised 38.5% of sequenced
cases in February (Figure 2). In the Interior, it appears that Epsilon, which was first detected 6
January 2021, was able to establish itself before B.1.1.519. However, one month after B.1.1.519
was first detected in the Interior, B.1.1.519 overtook Epsilon. By April, the majority of sequenced
cases were assigned to B.1.1.519 in the Interior (77.2%) and the Anchorage-Mat Su (72.6%).
After peaking in April, prevalence of B.1.1.519 in May only marginally decreased for the Interior
to 74.1% but sharply decreased for the Anchorage-Mat Su region to 38.8% (Figure 2).

191 The sharp decline of B.1.1.519 in the Anchorage-Mat Su region may have occurred earlier 192 than in the Interior due to the emergence of other variants that had established themselves in the 193 Anchorage-Mat Su region well before the Interior. For example, in the Anchorage-Mat Su region, 194 Alpha was detected on 20 December 2020 — 97 days before it was first detected in the Interior. 195 This gave Alpha more time to establish itself within the population and consequently reached 196 42.9% of sequenced cases by May in the Anchorage-Mat Su region versus 9.8% in the Interior. 197 Delta also emerged in the Anchorage-Mat Su region weeks before it was first detected in the 198 Interior, highlighting why B.1.1.519 may have persisted in Interior populations with the last case 199 of B.1.1.519 detected two weeks after last detection in the Anchorage-Mat Su.

200 High prevalence of B.1.1.519 in Alaska driven by founder effect and mutational advantage

201 Mutations in the SARS-CoV-2 genomes from Alaskan cases occurred in an almost 202 clockwise fashion (Figure 3B). Although most of these mutations are expected to have neutral 203 effects, some changes can confer selective advantages that enhance fitness by increasing 204 immune evasion, transmissibility, and/or infectivity (Korber et al., 2020). Mutations that cause 205 amino acid changes to the spike (S) glycoprotein may confer selective advantages given the role 206 of the S protein in COVID-19 pathogenesis and tropism. The mature S protein is cleaved into a 207 fusion domain (S2), and a S1 domain containing an N-terminal head and the receptor binding 208 domain (RBD) that binds to host cell human angiotensin converting enzyme-2 (hACE2) receptor.

Emergence of B.1.1.519 in Alaska

The S1 domain and RBD particularly are key targets for binding of neutralizing antibodies induced by infection or vaccines, principally IgG (Walls et al., 2020). Given the role of the S protein in receptor binding and subsequent membrane fusion and viral entry into host cells, mutations affecting S1, especially the RBD, can impact hACE2 affinity, viral entry, infectivity, and immune evasion (Berger & Schaffitzel, 2020; Hadi-Alijanvand & Rouhani, 2020).

214 B.1.1.519 has 11 shared amino acid (AA) mutations relative to the original SARS-CoV-2 215 (Wuhan-1) genome, with 4 in S: T478K and D614G in the RBD, P681H in the S1/S2 cleavage 216 site, and T732A in the S2 domain (Rodriguez-Maldonado 2021). T478K also arose in B.1.617.2 217 (Delta) (Jhun, 2021) and may contribute to antibody evasion (Di Giacomo et al., 2021). P681H 218 also occurs in B.1.1.7 (Alpha) and has a weak ability to increase proteolytic cleavage of S1/S2 in 219 vitro (Lubinskiet et al., 2021). The functional significance of B.1.1.519 harboring these mutations 220 in S is unclear and in a study from the Netherlands there was no evidence of increased viral load 221 conferred by B.1.1.519 (Gorgels et al., 2022).

222 Interestingly, based on the regression of total AA changes over time, which exhibited an 223 increase at a steady rate, B.1.1.519 genomes had fewer total AA changes across the genome 224 than predicted (Figure 3A) but aligned with the number of spike protein AA changes (Figure 3B). 225 B.1.1.519 had significantly more AA substitutions in the spike protein than lineages detected in 226 Alaska prior to the week of B.1.1.519's peak prevalence, 4 April 2021, suggesting a potential 227 competitive advantage over previously circulating lineages (B.1.1.519 = 4.18 ± 0.01 , Pre-peak 228 lineages = 2.65 ± 0.10 S AA substitutions, Wilcoxon W = 42302, p-value < 2e-16; Figure 3C). 229 Genomes sequenced after B.1.1.519's peak prevalence had significantly more AA changes in the 230 spike protein than B.1.1.519, dominated by more divergent Alpha and Delta VOC that emerged 231 after B.1.1.519's peak (Post-peak lineages = 7.75 ± 0.07 S AA substitutions, Wilcoxon W = 1e+05, 232 p-value < 2e-16; Figure 3C). These VOC likely held a selective advantage that allowed them to 233 outcompete B.1.1.519 in Alaska, a phenomenon of variant replacement observed across Alpha 234 and Delta waves in the USA (Lambrou et al., 2022).

Emergence of B.1.1.519 in Alaska

235 B.1.1.519 established itself within the circulating population of SARS-CoV-2 viruses in 236 Alaska weeks before other variants, such as Alpha, were consistently detected (Figure 1B). The 237 difference in prevalence of B.1.1.519 during Alpha's emergence in Alaska versus the Lower 48, 238 paired with the finding of more S protein amino acid changes in this variant than previous lineages 239 in Alaska, suggests that in Alaska B.1.1.519 likely emerged and became dominant due to a 240 founder effect. In this context, the founder effect results in reduction of genetic diversity from a 241 founding lineage of SARS-CoV-2 outcompeting the previously circulating lineages because of a 242 selective advantage that the founding population already possessed. The same trend was likely 243 not possible in the other states because Alpha, which proved to outcompete B.1.1.519, had 244 already established itself within the population, outcompeting B.1.1.519 when it emerged. 245 However, other locations displayed similar patterns to Alaska in terms of B.1.1.519's emergence 246 and spread, most notably Mexico. B.1.1.519 was first detected in Mexico in November 2020, 247 about three months prior to Alaska's first detection, and was found to rapidly outcompete existing 248 variants to become the dominant variant in the country, comprising 51.5% of sequenced genomes 249 by January 2021 (Rodríguez-Maldonado et al., 2020). By February, 90.9% of Mexico City's 250 sequenced cases were B.1.1.519. In a study examining the clinical impacts of B.1.1.519 in Mexico 251 City, Cedro-Tanda (2020) found that B.1.1.519-infected patients had a significant increase in 252 adjusted odds ratio for developing severe symptoms of COVID-19 including dyspnea, chest pain 253 and cyanosis, and hospitalizations compared to non-B.1.1.519 infected patients. Unfortunately, 254 we lacked the availability of the necessary data for Alaska to draw conclusions about the clinical 255 impacts of B.1.1.519 in Alaska as shown in the Mexico-City study. Another study, from the 256 Netherlands, describes a cluster of cases associated with B.1.1.519 demonstrating a high within 257 facility attack rate (Gorgels et al., 2022). Interestingly, that same study did not find differences in 258 B.1.1.519 viral loads compared with other variants, and sample size limited conclusions about 259 disease severity.

Emergence of B.1.1.519 in Alaska

260 Conclusions

261 Using genomic data, we identified the unique dynamics of B.1.1.519 spread in Alaska 262 compared to the contiguous United States. The distinct pattern of emergence and spread in 263 Alaska emphasizes both how founder events impact regional differences in circulating SARS-264 CoV-2 lineages and the significance of having robust sequencing efforts in place to detect this 265 variation. There are several resources that compile SARS-CoV-2 sequence data to help examine 266 patterns of emergence and spread. One such resource, outbreak.info, uses genomic data from 267 the sequence repository GISAID to estimate prevalence, emergence, and spread of SARS-CoV-268 2 lineages globally (Mullen et al., 2020). When considering data from this source, the highest 269 worldwide prevalence of B.1.1.519 was in early March 2021, a month before Alaska's peak 270 prevalence. At a country level, B.1.1.519 was found to comprise the highest percentage of 271 sequenced genomes in Mexico (15% of sequenced cases compared to 1% of cases sequenced 272 in the United States) over the course of the pandemic. On 14 February 2022, when this analysis 273 was conducted, B.1.1.519 comprised 10.4% of all of Alaska's SARS-CoV-2 sequences to date. 274 While this is high compared to other geographical locations, spatial and temporal heterogeneity 275 in sequencing efforts is known to bias genomic surveillance and complicate comparisons between 276 locations.

277 In Alaska, disparate sequencing coverage affected our ability to generate robust analyses 278 in rural regions of the state where sampling and subsequent sequencing efforts were lower than 279 more populated regions. Despite this disparate coverage, genomic surveillance continues to be 280 an essential tool for informing public health decision-making throughout the state. Genomic 281 surveillance paired with epidemiological findings will be key to detecting new threats as they 282 emerge and is a critical tool in shaping policy to address the clinical impacts of local variation in 283 circulating virus lineages. At a patient level, variant surveillance can inform which monoclonal 284 antibodies will be most effective for early treatment to directly reduce individual mortality and

Emergence of B.1.1.519 in Alaska

285	morbidity. At a community level, variant proportion data paired with epidemiological findings can
286	inform the broader population of their risks of reinfection, evaluate vaccine efficacy, and assess
287	the need for appropriate treatment stockpiles and quantities. This information will be of great
288	importance for public health policy decisions as SARS-CoV-2 becomes endemic in Alaska and
289	around the globe.

290

291

292 **Data Availability Statement**: All data used in this study are available online at GISAID 293 (https://www.gisaid.org/) and NCBI GenBank (https://www.ncbi.nlm.nih.gov/sars-cov-2/).

294 Funding

Work presented here was supported by Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) from the Centers for Disease Control and Prevention and a supplement award to Alaska INBRE, an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number 2P20GM103395.

300

301 Acknowledgments

We gratefully acknowledge the researchers responsible for obtaining the specimens and the laboratories where genetic sequence data were generated and shared via the GISAID Initiative and NCBI GenBank, on which this research is based.

305

Emergence of B.1.1.519 in Alaska

306 References.

- Aksamentov, I., Roemer, C., Hodcroft, E. B., & Neher, R. A., (2021). Nextclade: clade
 assignment, mutation calling and quality control for viral genomes. Journal of Open
 Source Software, 6(67), 3773.
- Alaska Department of Labor and Workforce Development, 2020 Population Estimates by
 Borough, Census Area, and Economic Region. Nov 5, 2021.
 https://live.laborstats.alaska.gov/pop/index.cfm
- Alaska Department of Health and Social Services (Alaska DHSS) COVID-19 CSV Files
 Database. Nov 5, 2021.
 - https://experience.arcgis.com/experience/b2f5a105a41c4ca88024efbc2c2e868f/
- Berger, I., & Schaffitzel, C. (2020). The SARS-CoV-2 spike protein: balancing stability and
 infectivity. *Cell research*, *30*(12), 1059-1060.
- Centers for Disease Control and Prevention (CDC) United States COVID-19 Cases, Deaths,
 and Laboratory Testing (NAATs) by State, Territory, and Jurisdiction. Nov 5, 2021.
 https://covid.cdc.gov/covid-data-tracker/#cases_community
- Cedro-Tanda, A.; Gómez-Romero, L.; Alcaraz, N.; de Anda-Jauregui, G.; Peñaloza, F.; Moreno,
 B.; Escobar-Arrazola, M.A.; Ramirez-Vega, O.A.; Munguia-Garza, P.; Garcia-Cardenas,
 F.; Cisneros-Villanueva, M.; Moreno-Camacho, J.L.; Rodriguez-Gallegos, J.; Luna-Ruiz
 Esparza, M.A.; Fernández Rojas, M.A.; Mendoza-Vargas, A.; Reyes-Grajeda, J.P.;
 Campos-Romero, A.; Angulo, O.; Ruiz, R.; Sheinbaum-Pardo, C.; Sifuentes-Osornio, J.;
 Kershenobich, D.; Hidalgo-Miranda, A.; Herrera, L.A. (2021). The Evolutionary
 Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City.
- 328 *Viruses*, *13*, 2182.
- Di Giacomo, S., Mercatelli, D., Rakhimov, A., & Giorgi, F. M. (2021). Preliminary report on
 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. *Journal of medical virology*, *93*(9), 5638-5643.
- Elbe, S., & Buckland-Merrett, G. (2017). Data, disease and diplomacy: GISAID's innovative
 contribution to global health. *Global challenges (Hoboken, NJ)*, 1(1), 33–46.
- Gorgels, K. M., Dingemans, J., van der Veer, B. M., Hackert, V., Hensels, A. Y., den Heijer, C.
 D., den Heijer, C.D., van Alphen, L.B., Savelkoul, P.H., & Hoebe, C. J. (2022). Linked
 nosocomial COVID-19 outbreak in three facilities for people with intellectual and
 developmental disabilities due to SARS-CoV-2 variant B. 1.1. 519 with spike mutation
- 338 T478K in the Netherlands. *BMC infectious diseases*, 22(1), 1-9.
- Hadi-Alijanvand, H., & Rouhani, M. (2020). Studying the effects of ACE2 mutations on the
 stability, dynamics, and dissociation process of SARS-CoV-2 S1/hACE2 complexes. *Journal of proteome research*, *19*(11), 4609-4623.
- John Hopkins Coronavirus Resource Center. Impact of Opening and Closing Decisions by
 State. March 9, 2022. <u>https://coronavirus.jhu.edu/data/state-timeline/new-confirmed-</u>
 <u>cases/alaska/</u>
- Jhun, H., Park, H. Y., Hisham, Y., Song, C. S., & Kim, S. (2021). SARS-CoV-2 Delta (B. 1.617.
 2) variant: a unique T478K mutation in receptor binding motif (RBM) of spike gene. *Immune Network*, 21(5).

Emergence of B.1.1.519 in Alaska

348	Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., & Montefiori,
349	D. C. (2020). Tracking changes in SARS-CoV-2 spike: evidence that D614G increases
350	infectivity of the COVID-19 virus. Cell, 182(4), 812-827.
351	Lambrou, A. S., Shirk, P., Steele, M. K., Paul, P., Paden, C. R., Cadwell, B., Reese, H.E., Aoki,
352	Y., Hassell, N., Zheng, X.Y., & Emerging Variants NS3 Working Group. (2022). Genomic
353	Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B. 1.617. 2) and
354	Omicron (B. 1.1. 529) Variants—United States, June 2021–January 2022. Morbidity and
355	Mortality Weekly Report, 71(6), 206.
356	Lubinski, B., Fernandes, M. H., Frazier, L., Tang, T., Daniel, S., Diel, D. G., Jaimes, J.A., &
357	Whittaker, G. R. (2022). Functional evaluation of the P681H mutation on the proteolytic
358	activation of the SARS-CoV-2 variant B. 1.1. 7 (Alpha) spike. Iscience, 25(1), 103589.
359	Mullen, J.L., Tsueng, G., Latif, A.A., Alkuzweny, M., Cano, M., Haag, E., Zhou, J., Zeller, M.,
360	Hufbauer, E., Matteson, N., Andersen, K.G., Wu, C., Su, A.I., Gangavarapu, K., Hughes,
361	L.D. (2020) Center for Viral Systems Biology outbreak.info. Available online:
362	https://outbreak.info/
363	O'Toole, Á., Scher, E., Underwood, A., Jackson, B., Hill, V., McCrone, J. T., & Rambaut, A.
364	(2021). Assignment of epidemiological lineages in an emerging pandemic using the
365	pangolin tool. Virus Evolution, 7(2), veab064.
366	Rambaut, A., Holmes, E. C., O'Toole, Á., Hill, V., McCrone, J. T., & Ruis, C. A dynamic
367	nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat
368	Microbiol. 2020 Jul 15; 1–5.
369	Rodríguez-Maldonado, A. P., Vázquez-Pérez, J. A., Cedro-Tanda, A., Taboada, B., Boukadida,
370	C., Wong-Arámbula, C., Nuñez-García, T. E., Cruz-Ortiz, N., Barrera-Badillo, G.,
371	Hernández-Rivas, L., López-Martínez, I., Mendoza-Vargas, A., Reyes-Grajeda, J. P.,
372	Alcaraz, N., Peñaloza-Figueroa, F., Gonzalez-Barrera, D., Rangel-DeLeon, D., Herrera-
373	Montalvo, L. A., Mejía-Nepomuceno, F., Hernández-Terán, A., Ramírez-González, J.
374	E. (2021). Emergence and spread of the potential variant of interest (VOI) B.1.1.519 of
375	SARS-CoV-2 predominantly present in Mexico. Archives of virology, 166(11), 3173-
376	3177.
377	Shu, Y., & McCauley, J. (2017). GISAID: Global initiative on sharing all influenza data-from
378	vision to reality. <i>Eurosurveillance</i> , 22(13), 30494.
379	United States Census Bureau. QuickFacts Alaska. July 1,2021.
380	https://www.census.gov/quickfacts/fact/table/AK#
381	Walensky, R. P., Walke, H. T., & Fauci, A. S. (2021). SARS-CoV-2 variants of concern in the
382	United States—Challenges and opportunities. <i>Jama</i> , <i>325</i> (11), 1037-1038.
383	World Health Organization (WHO) Tracking SARS-CoV-2 Variants. Nov 5, 2021.
384	https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
385	Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020).
386	Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. <i>Cell</i> , 181(2),
387	281-292.

Emergence of B.1.1.519 in Alaska

Figure Legends

Figure 1. (A and C) Daily case count (bars) and seven day rolling average (red line) and (B and D) percent of sequences (estimated prevalence) by PANGO lineages detected by week from 2020-11-29 to 2021-06-26 for Alaska (A and B) and the Lower 48 (C and D).

Figure 2. Percent of sequenced cases (estimation of prevalence) by PANGO lineage by month for the (A) Anchorage-Mat Su and (B) Interior regions of Alaska from December 2020 through June 2021.

Figure 3. Scatterplots depicting the A) S protein amino acid (AA) substitutions and the (B) total AA substitutions over time. Data includes each genome from an Alaskan confirmed case, colored by variant. The gray line shows a generalized linear model regression of data.(C) Boxplot of number of S protein AA substitutions per genome from sequences pre-peak prevalence of B.1.1.519 on 2021-04-04, B.1.1.519, and post peak prevalence genomes. Diamonds depict the mean number of AA substitutions. Points are individual genomes colored by lineage. Wilcoxon test between group significance p < 0.0001 ****, p < 0.05 *, ns >0.1.

Emergence of B.1.1.519 in Alaska



Figure 1. (A and C) Daily case count (bars) and seven day rolling average (red line) and (B and D) percent of sequences (estimated prevalence) by PANGO lineages detected by week from 2020-11-29 to 2021-06-26 for Alaska (A and B) and the Lower 48 (C and D).

Emergence of B.1.1.519 in Alaska



Figure 2. Percent of sequenced cases (estimation of prevalence) by PANGO lineage by month for the (A) Anchorage-Mat Su and (B) Interior regions of Alaska from December 2020 through June 2021.

Emergence of B.1.1.519 in Alaska



Figure 3. Scatterplots depicting the (A) S protein amino acid (AA) substitutions and the (B) total AA substitutions over time. Data includes each genome from an Alaskan confirmed case, colored by variant. The gray line shows a generalized linear model regression of data. (C) Boxplot of number of S protein AA substitutions per genome from sequences pre-peak prevalence of B.1.1.519 on 2021-04-04, B.1.1.519, and post peak prevalence genomes. Diamonds depict the mean number of AA substitutions. Points are individual genomes colored by lineage. Wilcoxon test between group significance p < 0.0001 ****, p < 0.05 *, ns >0.1.

Emergence of B.1.1.519 in Alaska



Supplemental Figures.

Figure S1. (A) Number of detected B.1.1.519 genomes per 100k people by Alaska economic region over time. Lines are colored by Alaska economic region. (B) Estimated prevalence of emerging lineages by Alaska economic region from December 2020 through June 2021.



Figure S2. Number of cases sequenced (bars) and the proportion of total cases sequenced in the Anchorage-Mat Su and Interior economic regions of Alaska.